Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Published on Apr 13, 2017in Bioconjugate Chemistry4.031
· DOI :10.1021/ACS.BIOCONJCHEM.7B00062
Xiuxia Sun6
Estimated H-index: 6
(ImmunoGen, Inc.),
Jose F. Ponte10
Estimated H-index: 10
(ImmunoGen, Inc.)
+ 18 AuthorsJohn M. Lambert52
Estimated H-index: 52
Sources
Abstract
Antibody–drug conjugates (ADCs) are being actively pursued as a treatment option for cancer following the regulatory approval of brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla). ADCs consist of a cytotoxic agent conjugated to a targeting antibody through a linker. The two approved ADCs (and most ADCs now in the clinic that use a microtubule disrupting agent as the payload) are heterogeneous conjugates with an average drug-to-antibody ratio (DAR) of 3–4 (potentially ranging from 0 to 8 for individual species). Ado-trastuzumab emtansine employs DM1, a semisynthetic cytotoxic payload of the maytansinoid class, which is conjugated via lysine residues of the antibody to an average DAR of 3.5. To understand the effect of DAR on the preclinical properties of ADCs using maytansinoid cytotoxic agents, we prepared a series of conjugates with a cleavable linker (M9346A–sulfo-SPDB–DM4 targeting folate receptor α (FRα)) or an uncleavable linker (J2898A–SMCC–DM1 targeting the epidermal growth fac...
📖 Papers frequently viewed together
1,209 Citations
726 Citations
635 Citations
References26
Newest
#1Jose F. Ponte (ImmunoGen, Inc.)H-Index: 10
#2Xiuxia Sun (ImmunoGen, Inc.)H-Index: 6
Last. John M. Lambert (ImmunoGen, Inc.)H-Index: 52
view all 16 authors...
Antibody-drug conjugates (ADCs) have become a widely investigated modality for cancer therapy, in part due to the clinical findings with ado-trastuzumab emtansine (Kadcyla). Ado-trastuzumab emtansine utilizes the Ab-SMCC-DM1 format, in which the thiol-functionalized maytansinoid cytotoxic agent, DM1, is linked to the antibody (Ab) via the maleimide moiety of the heterobifunctional SMCC linker. The pharmacokinetic (PK) data for ado-trastuzumab emtansine point to a faster clearance for the ADC tha...
33 CitationsSource
#1Cornelius Cilliers (UM: University of Michigan)H-Index: 7
#2Hans Guo (UM: University of Michigan)H-Index: 1
Last. Greg M. Thurber (UM: University of Michigan)H-Index: 23
view all 5 authors...
Antibody-drug conjugates exhibit complex pharmacokinetics due to their combination of macromolecular and small molecule properties. These issues range from systemic concerns, such as deconjugation of the small molecule drug during the long antibody circulation time or rapid clearance from nonspecific interactions, to local tumor tissue heterogeneity, cell bystander effects, and endosomal escape. Mathematical models can be used to study the impact of these processes on overall distribution in an ...
41 CitationsSource
#1Bart De Goeij (Genmab)H-Index: 7
#2John M. Lambert (ImmunoGen, Inc.)H-Index: 52
The clinical success of Adcetris ® (brentuximab vedotin) and Kadcyla ® (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting ...
154 CitationsSource
#1Kalli C. Catcott (ImmunoGen, Inc.)H-Index: 4
#2Molly A. McShea (ImmunoGen, Inc.)H-Index: 4
Last. Nicholas C. Yoder (ImmunoGen, Inc.)H-Index: 15
view all 14 authors...
ABSTRACTAntibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by purification and biochemical analysis techniques that necessitate burdensome quantities of antibody. Here we describe a method, developed for the maytansinoid class of ADCs, enabling parallel conjugation of antibodies in 96-well format. The method utilizes ∼100 µg of antibody per well and requires <5 µg of ADC for characterization. We demo...
13 CitationsSource
#2Mao YinH-Index: 6
Last. Timothy B. LowingerH-Index: 4
view all 12 authors...
Antibody–drug conjugates (ADC) are an emerging drug class that uses antibodies to improve cytotoxic drug targeting for cancer treatment. ADCs in current clinical trials achieve a compromise between potency and physicochemical/pharmacokinetic properties by conjugating potent cytotoxins directly to an antibody at a 4:1 or less stoichiometric ratio. Herein, we report a novel, polyacetal polymer-based platform for creating ADC that use poly-1-hydroxymethylethylene hydroxymethyl-formal (PHF), also kn...
48 CitationsSource
#1Pavel Strop (Pfizer)H-Index: 22
#2Kathy Delaria (Pfizer)H-Index: 8
Last. Arvind RajpalH-Index: 32
view all 22 authors...
Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
62 CitationsSource
#1Robert P. Lyon (Seattle Genetics)H-Index: 12
#2Tim D. Bovee (Seattle Genetics)H-Index: 6
Last. Peter D. Senter (Seattle Genetics)H-Index: 73
view all 10 authors...
The in vivo efficacy of antibody-drug conjugates is enhanced by decreasing their hydrophobicity.
206 CitationsSource
#1Olga Ab (ImmunoGen, Inc.)H-Index: 10
#2Kathleen R. Whiteman (ImmunoGen, Inc.)H-Index: 13
Last. John M. Lambert (ImmunoGen, Inc.)H-Index: 52
view all 13 authors...
A majority of ovarian and non–small cell lung adenocarcinoma cancers overexpress folate receptor α (FRα). Here, we report the development of an anti-FRα antibody–drug conjugate (ADC), consisting of a FRα-binding antibody attached to a highly potent maytansinoid that induces cell-cycle arrest and cell death by targeting microtubules. From screening a large panel of anti-FRα monoclonal antibodies, we selected the humanized antibody M9346A as the best antibody for targeted delivery of a maytansinoi...
79 CitationsSource
#1Christina Vasalou (Novartis)H-Index: 2
#2Gabriel Helmlinger (Novartis)H-Index: 17
Last. Bruce Gomes (Novartis)H-Index: 2
view all 3 authors...
Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading to large untargeted regions that escape therapy. We present a modeling framework which includes the systemic distribution, vascular permeability, interstitial transport, as well as binding and payload rel...
45 CitationsSource
#1Victor S. Goldmacher (ImmunoGen, Inc.)H-Index: 55
#2Godfrey W. Amphlett (ImmunoGen, Inc.)H-Index: 5
Last. Alexandru C. Lazar (ImmunoGen, Inc.)H-Index: 15
view all 4 authors...
The maytansinoid antibody–drug conjugates (ADCs) in clinical development for cancer therapy each contain a derivative of the microtubule-targeting agent, maytansine, covalently attached to the antibody via an engineered linker. A sample of any of these conjugates contains molecules with different numbers of maytansinoid molecules, or “drug” loads, the relative abundance of which can be determined by mass spectrometry. We examined the accuracy of the Poisson distribution and the binomial distribu...
13 CitationsSource
Cited By58
Newest
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogenous leukemia, several ADCs have been developed for the treatment of cancer. The goal of an ADC as a cancer agent is to release the cytotoxic drug to kill the tumor cells without harming the normal or h...
Source
#1Zheng Su (SPU: Shenyang Pharmaceutical University)
#2Xiao DianH-Index: 1
Last. Li Song (SPU: Shenyang Pharmaceutical University)H-Index: 1
view all 8 authors...
Abstract Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody‒drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor. However, existing linkers often release payloads nonspecifically and inevitably lead to off-target toxicity. This defect is becoming an ...
Source
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Elias Jabbour (University of Texas MD Anderson Cancer Center)H-Index: 80
#2Shilpa Paul (University of Texas MD Anderson Cancer Center)H-Index: 6
Last. Hagop M. Kantarjian (University of Texas MD Anderson Cancer Center)H-Index: 232
view all 3 authors...
Advances in our understanding of cancer biology have enabled drug development to progress towards better targeted therapies that are both more effective and safer owing to their lack of off-target toxicities. In this regard, antibody–drug conjugates (ADCs), which have the potential to combine the selectivity of therapeutic antibodies with the cytotoxicity of highly toxic small molecules, are a rapidly developing drug class. The complex and unique structure of an ADC, composed of a monoclonal ant...
Source
After significant effort over the last 30 years, antibody-drug conjugates (ADCs) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date, with additional ADCs in late stages of development. Here we introduce Dolaflexin, a novel ADC technology that overcomes key limitations of the most common ADC platforms with two key features: a higher drug-antibody ratio and a novel auristatin with a controlled bystander effect. The novel, cell permeable pay...
2 CitationsSource
#1Joshua Z. Drago (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#1Joshua Z. Drago (Cornell University)
Last. Sarat Chandarlapaty (Cornell University)H-Index: 50
view all 3 authors...
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The primary goal of ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic delivery to cells that express the target antigen of interest. Advances in synthetic biochemistry have ushered in a new generation of ADCs, which promise to improve upon the tissue specificity and cytotoxicity of their predecessors. M...
4 CitationsSource
#1Stephen J. Walsh (University of Cambridge)H-Index: 8
#2Jonathan D. Bargh (University of Cambridge)H-Index: 4
Last. David R. Spring (University of Cambridge)H-Index: 62
view all 14 authors...
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly in oncology, as discrimination between healthy and malignant tissues or cells can be achieved. Nine ADCs have received approval from the US Food and Drug Administration and more than 80 others are currently undergoing clinical investigations for a range of solid tumours and h...
7 CitationsSource
#1Fatma Betul Arslan (Hacettepe University)H-Index: 3
#2Kivilcim Ozturk Atar (Hacettepe University)H-Index: 2
Last. Sema Çalış (Hacettepe University)H-Index: 23
view all 3 authors...
Abstract Passive and active targeted nanoparticulate delivery systems show promise to compensate for lacking properties of conventional therapy such as side effects, insufficient effiency and accumulation of the drug at target site, poor pharmacokinetic properties etc. For active targeting, physically or covalently conjugated ligands, including monoclonal antibodies and their fragments, are consistently used and researched for targeting delivery systems or drugs to their target site. Currently, ...
1 CitationsSource
#1Durgesh V. Nadkarni (Pfizer)H-Index: 6
#2Jamie Lee (Pfizer)H-Index: 1
Last. Debra M. Meyer (Pfizer)H-Index: 11
view all 7 authors...
Antibody-drug conjugates (ADCs) consist of a target-specific antibody that is covalently conjugated to a drug via a linker. ADCs are designed to deliver cytotoxic drugs (payloads), specifically to cancer cells, while minimizing systemic toxicity. Conventional cysteine conjugation typically results in the formation of ADC molecules containing a heterogeneous mixture of 2, 4, 6, and 8 drug-loaded species. The drug-to-antibody ratio (DAR) of the mixture represents the weighted average of these spec...
Source
#1Jose F. PonteH-Index: 10
#2Leanne LanieriH-Index: 8
Last. Greg M. Thurber (UM: University of Michigan)H-Index: 23
view all 15 authors...
Several antibody-drug conjugates (ADCs) showing strong clinical responses in solid tumors target high expression antigens (HER2, TROP2, Nectin-4, and folate receptor alpha/FRα). Highly expressed tumor antigens often have significant low-level expression in normal tissues, resulting in the potential for target-mediated drug disposition (TMDD) and increased clearance. However, ADCs often do not cross-react with normal tissue in animal models used to test efficacy (typically mice), and the impact o...
1 CitationsSource